Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
BACKGROUND
Gender differences in the use of recombinant tissue-type plasminogen activator (r-tPA) in stroke are complicated. In this study, we investigated gender differences using r-tPA exclusion criterion in a stroke population.


METHODS
We analyzed the data from ischemic stroke patients aged 18 years or older from the Greenville Health System stroke registry on r-tPA administration between January 2010 and December 2013. We identified exclusion criterion and used specific clinical factors to determine gender differences in stroke patients receiving r-tPA.


RESULTS
Of the 633 patients who were eligible to receive r-tPA, less than half received r-tPA (n = 241) whereas 422 were not able to receive r-tPA. Of the 241 patients who received r-tPA, 49.4% were female and 50.6% were male. Of the 422 patients who did not receive r-tPA, more women (235) were excluded from r-tPA than men (187) (P < .05). There were no gender differences in warning signs and contraindications in female versus male stroke patients (P > .005). There were however gender differences in age group as more women (38%; n = 235) were more likely to be excluded if they are more than 80 years old than men (19%, n = 187).


CONCLUSIONS
Within a large stroke population, exclusion criteria for r-tPA in women and men were similar with regard to race, initial National Institutes of Health Stroke Scale score, warning signs, and contraindications, but were different in the age group population exclusion criterion for intravenous r-tPA. We observed that intracerebral hemorrhage and match on computed tomography perfusion/magnetic resonance imaging or visible infarct greater than one third of the middle cerebral artery distribution were absolute criteria for exclusion.
University of South Carolina School of Medicine, Greenville, South Carolina.
Megan
M
Fredwall
Greenville Health System, Greenville, South Carolina.
Shannon
S
Sternberg
Greenville Health System, Greenville, South Carolina.
Dawn
D
Blackhurst
University of South Carolina School of Medicine, Greenville, South Carolina.
Andrew
A
Lee
Greenville Health System, Greenville, South Carolina.
Rodney
R
Leacock
University of South Carolina School of Medicine, Greenville, South Carolina. Electronic address: nathanit@greenvillemed.sc.edu.
Thomas I
TI
Nathaniel
D000368:Aged; D000369:Aged, 80 and over; D004185:Disability Evaluation; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D054625:Healthcare Disparities; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D055420:Perfusion Imaging / Q000379:methods; D011237:Predictive Value of Tests; D017064:Process Assessment, Health Care; D011994:Recombinant Proteins / Q000008:administration & dosage; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D013022:South Carolina; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D014057:Tomography, X-Ray Computed
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator
Gender; contraindication; ischemic stroke; recombinant tissue-type plasminogen activator (r-tPA)